Trials / Unknown
UnknownNCT04435652
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel for Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 492 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who had tumor progression after first-line treatment with platinum and fluoropyrimidine doublet therapy. The study will be conducted in 2 parts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QL1604 | 3mg/kg, D1,8,15,Q4w, IV infusion |
| DRUG | Nab-paclitaxel | 100mg/m2, D1,8,15,Q4w, IV infusion |
| DRUG | Paclitaxel | 80mg/m2, D1,8,15,Q4w, IV infusion |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2022-04-30
- Completion
- 2022-11-30
- First posted
- 2020-06-17
- Last updated
- 2020-06-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04435652. Inclusion in this directory is not an endorsement.